
|Videos|December 13, 2022
COSMIC-313 and Advice to Community Oncologists Treating Advanced RCC
Author(s)Eric Jonasch, MD
Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5










































